Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.
CD4+ T cells
CD8+ T cells
GIST
Gastrointestinal stromal tumor
IFN-γ signaling pathway
M2 macrophages
PD-L1 expression
TIL
checkpoint inhibitor
imatinib
immunotherapy
tumor-infiltrating lymphocytes
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
14
12
2018
revised:
30
04
2019
accepted:
01
05
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
epublish
Résumé
Few studies were conducted investigating the immunological profiles in gastrointestinal stromal tumors (GIST). Adaptive and innate immune cells are present in the tumor microenvironment, indicating GIST as inflamed tumors. In addition, murine models suggested a potential interaction between immune components and imatinib. In this retrospective study, the GIST immunological profile was investigated through
Identifiants
pubmed: 31428517
doi: 10.1080/2162402X.2019.1617588
pii: 1617588
pmc: PMC6685519
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e1617588Références
N Engl J Med. 2002 Aug 15;347(7):472-80
pubmed: 12181401
Blood. 2003 Oct 15;102(8):2868-76
pubmed: 12829584
J Clin Invest. 2004 Aug;114(3):379-88
pubmed: 15286804
Lancet. 2006 Oct 14;368(9544):1329-38
pubmed: 17046465
Mol Cancer Ther. 2009 Aug;8(8):2172-82
pubmed: 19671739
Int J Cancer. 2010 Aug 15;127(4):899-909
pubmed: 20013807
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Nat Med. 2011 Jun;17(6):700-7
pubmed: 21552268
Nat Med. 2011 Aug 28;17(9):1094-100
pubmed: 21873989
Lancet. 2013 Jan 26;381(9863):295-302
pubmed: 23177515
Cancer Res. 2013 Jun 15;73(12):3499-510
pubmed: 23592754
J Exp Med. 2013 Nov 18;210(12):2495-502
pubmed: 24145512
BMC Cancer. 2014 Sep 20;14:685
pubmed: 25239601
Hum Pathol. 2015 Mar;46(3):357-65
pubmed: 25540867
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Oncoimmunology. 2015 Feb 3;4(5):e1002729
pubmed: 26155391
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Clin Cancer Res. 2017 Jan 15;23(2):454-465
pubmed: 27470968
J Invest Dermatol. 2017 Feb;137(2):484-493
pubmed: 27608549
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Clin Cancer Res. 2017 Jun 15;23(12):2972-2980
pubmed: 28007774
Cancer Gene Ther. 2017 Mar;24(3):130-133
pubmed: 28186088
Oncoimmunology. 2016 Apr 25;6(1):e1137418
pubmed: 28197361
Cancer Immunol Immunother. 2017 Sep;66(9):1175-1187
pubmed: 28451792
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Genome Biol. 2017 Jul 5;18(1):128
pubmed: 28679399
Histopathology. 2018 Feb;72(3):405-413
pubmed: 28871595
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442
Cancer Immunol Res. 2018 Apr;6(4):434-447
pubmed: 29467128
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
J Clin Invest. 2019 Feb 14;129(5):1863-1877
pubmed: 30762585
Biochem J. 1997 Oct 1;327 ( Pt 1):73-80
pubmed: 9355737
Oncogene. 1998 Jan 29;16(4):505-15
pubmed: 9484840